In a pioneering advance for regenerative medicine, a study published in Nature Biomedical Engineering has successfully integrated human organoids into pig kidneys using normothermic perfusion. This demonstrates for the first time that functional mini-organs can be inserted on a large scale into animal organs.

This technique could increase the availability of organs suitable for transplantation and adds to recent milestones in xenotransplantation. It also raises significant challenges for the future of cell therapy and tissue engineering.

The study, published in Nature Biomedical Engineering, was led by Dr. Nuria Montserrat, researcher at the Catalan Institution for Research and Advanced Studies (ICREA) and Minister of Research and Universities for the Government of Catalonia.

It describes how human organoids have been successfully inserted into pig kidneys using normothermic perfusion machines, achieving the integration of human cells into the animal’s organ.

Montserrat has been promoting the use of mini-organs in regenerative medicine for over 10 years.

Her team removed the kidneys from pigs and, after inserting the lab-grown human mini-kidneys into them, reimplanted them.

This breakthrough could in future improve the number of kidney transplants, using mini kidneys to repair damaged organs, given the shortage of organs available for transplant.

Organoids are mini organs produced in the laboratory from stem cells that proliferate, generating structures that mimic the function of real organs.

In this case, the mini kidneys were produced from human stem cells and are about the size of a pinhead. For the first time, they have been obtained in large quantities and cost-effectively, making their future application to human patients more feasible.

The next step will be to test this technique on human organs for implantation in people.

According to Montserrat “every year, more than 1,000 kidneys are discarded because they are not suitable for transplantation. Now we have the opportunity to use them for research.” The goal is to increase the number of kidneys available for transplantation.

Manufacturing functional human organoids is very complex, given that the kidney has 23 different cell types.

Pig organ transplants in humans

In 2024, the first transplant of a pig kidney into a living person suffering from severe kidney disease was performed at Massachusetts General Hospital. The patient died two months after the procedure.

This procedure in a living recipient marked a milestone in the field of xenotransplantation (the transplantation of organs or tissues from one species to another) as a possible solution to the shortage of organs worldwide.

In 2021, a pig kidney transplant was performed on a woman who was brain dead. The operation took place at the Langone Medical Center in New York and was a success, as the kidney functioned properly on its own for 54 hours.

Transplants of other pig organs have also been performed in humans.

In 2022, a pig heart was transplanted into a patient with a serious heart condition for whom there was no other treatment. The animal from which the heart came was genetically modified, altering 10 genes to reduce immune rejection.

Likewise, in 2024, the first xenotransplantation of a pig liver to a human took place. The recipient was a 50-year-old man who was brain dead and received a genetically modified pig liver that remained functional for 10 days.

Bioethical assessment

Advances in organoid research offer a promising future in regenerative medicine and, specifically, in the field of organ transplantation.

The biological barriers presented by xenotransplantation are being addressed through the application of gene editing with selective modification of genes involved in the activation of the immune response by the organ recipient.

Thus, the combination of human organoids with animal organs can generate tissues with better histocompatibility that can help alleviate the current shortage of organs suitable for transplantation.

However, the extensive application of these advances in clinical practice, the improvement of the compatibility process to avoid immunological rejections, and the increase in the safety of the gene editing techniques used are still pending.

Furthermore, the high cost of these processes, in addition to the time required for their development, necessitates new research to economize their development and increase their effectiveness.

In this case, the work we are now analyzing represents a very positive contribution given that the efficiency of the process has been improved and large quantities of organoids have been obtained at a cost-effective price, which has contributed to improving the viability of this technique in the future.

Julio Tudela and Ester Bosch

Bioethics Observatory – Institute of Life Sciences

Catholic University of Valencia

 

Share This Story, Choose Your Platform!